Giordano A, Smorlesi A, Frontini A, Barbatelli G, Cinti S
Pivotal data: STEP-1 (Wilding et al., NEJM 2021) reported 14.9 percent body-weight reduction at 2.4 mg weekly over 68 weeks, and SELECT (Lincoff et al., NEJM 2023) was the first demonstration that a GLP-1 agonist reduces cardiovascular events in a population without diabetes (20 percent MACE reduction)
Tirzepatide often produces greater average weight loss in studies, but the best choice depends on individual needs and tolerance
Some patients may explore compounded GLP-1 medications, manufacturer savings cards, or alternative dosing schedules when brand-name medications become too expensive or difficult to access consistently
When combined with other holistic therapies, such as acupuncture, physical therapy, and nutritional support, BPC-157 can enhance recovery and help patients achieve long-term health and vitality
In this carousel, youll discover how digital triage helps pharma move: From awareness to activation From traffic to measurable impact From content to clinical relevance Want to go deeper
